# A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

> **NCT02161224** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 16 (actual)

## Conditions studied

- PK of FG-4592
- Hepatic Insufficiency
- Healthy Subjects

## Interventions

- **DRUG:** FG-4592

## Key facts

- **NCT ID:** NCT02161224
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02161224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02161224, "A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02161224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*